Home > Pulmonology > NLC 2022 > Respiratory Failure > The role of CPAP and HFNC in COVID-19

The role of CPAP and HFNC in COVID-19

Conference
NLC 2022
Doi
https://doi.org/10.55788/116dfe67
Depending on the severity of COVID-19-induced respiratory disease, different treatment modalities can be applied regarding the use of continuously delivered continuous positive airway pressure (cCPAP) and high flow nasal cannula therapy (HFNC). By using cCPAP, an airflow is delivered to the airways by establishing a positive pressure which is maintained through the respiratory cycle. HFNC consists of warm, humified oxygen which is being delivered in a high flow by a nasal cannula. In patients with mild to moderate COVID-19, the target is acceptable SpO2 obtainable with ≤5 L O2/min (FiO2 0.4) oxygen therapy delivered by bi-nasal canula or air-entrainment mask. For patients with severe COVID-19, the target is acceptable SpO2 obtainable with 6-15 L O2/min (FiO2 0.4–0.6), and the ICU personnel should be advised about the patient’s condition. cCPAP is not contraindicated, whereas intermittent man...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on